ArticleJACC. Asia2026
7-Year Outcomes of Balloon-Expandable Versus Self-Expanding Valves in Women Undergoing Transcatheter Aortic Valve Replacement.
Article in JACC. Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- TAVR for Women: Are We Really Seeing the Long-Term Story.JACC. Asia · 2026Article
- Reply: TAVR for Women: Are We Really Seeing the Long-Term Story.JACC. Asia · 2026Article
- BEVs Versus SEVs in Women With Small Annuli: 7-Year Insights From the OCEAN-TAVI Registry.JACC. Asia · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFemale patients with aortic stenosis frequently present with a small aortic annulus (SAA), which may result in unfavorable echocardiographic cardiac function after transcatheter aortic valve replacement. However, evidence comparing the long-term outcomes of balloon-expandable valves (BEVs) and self-expanding valves (SEVs) in this context is limited.
objectivesThis study compares the 7-year clinical outcomes after transcatheter aortic valve replacement using BEV and SEV in female patients.
methodsOverall, 1,827 female patients treated with BEV and 805 treated with SEV were identified from the Optimized transCathEter vAlvular intervention-Transcatheter Aortic Valve Implantation (OCEAN-TAVI) registry. One-to-one propensity score matching (PSM) was performed to adjust for confounding factors, resulting in 744 matched patients per group. The primary clinical endpoints included all-cause mortality, stroke, and heart failure rehospitalization.
resultsOverall, 1,303 patients (87.6%) had a SAA. Echocardiographic assessments indicated that BEV had smaller effective orifice area and higher mean pressure gradient than did SEV throughout the follow-up period. In the PSM analysis, BEV was associated with lower all-cause mortality (51.5% vs 57.4%; log-rank, P = 0.021) and stroke at 7 years (10.8% vs 16.7%; Fine-Gray, P = 0.008). Heart failure rehospitalization rates were similar between groups. In multivariable analyses, valve type was not independently associated with long-term outcomes, and subgroup analyses considering annulus size yielded consistent results.
conclusionsFor women predominantly presenting with a SAA, BEV demonstrated decreased echocardiac performance compared with SEV. Although PSM analysis indicated more favorable outcomes with BEV, valve type was not independently associated with long-term prognosis after multivariable adjustment. These findings suggest that both types of transcatheter heart valves may be an acceptable option in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.